Market ExpansionARS Pharmaceuticals signed contracts with the three major group purchasing organizations, which cover 94% of all individual commercial payers, and the majority are covering neffy.
Marketing CampaignThe direct-to-consumer marketing campaign has already driven unaided awareness of neffy from about 20% before the campaign to 49% in late July.
Sales GrowthARS Pharma reported $12.8M in net product revenue from neffy in Type 1 allergy, demonstrating accelerating commercial momentum that validates the transformative potential of needle-free epinephrine.